Skip to content

effect of Virechana and Navakarshika Ghana vati in the management of kitibha with special Reference to psoriasis

Randomized controlled clinical Study to evaluate the efficacy of Virechana and Navakarshika Ghana Vati in the management of Kitibha with special reference to psoriasis - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101848
Enrollment
70
Registered
2026-01-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Department of Kayachikitsa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of Kitibha (Shyava, Kina, Khara Sparsha, Parusha) diagnosed by Ayurveda & psoriasis will be diagnosed by modern parameters. 2. Age group between 20-50 years of both the sex patients. 3. Patients having chronicity of psoriasis less than 5 years. 4. Patients are willing to participate in the above trial and give informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from any acute disease/any infectious disease, chronic disease/such as RA, SLE. 2.Any other skin disease in its association. 3.Patients suffering from systemic disorders like diabetes mellitus, cardiac& renal disorders, major liver disorders, immune-compromised hosts. 4.Pregnancy and lactating mothers. 5.Patients having complications of Psoriasis like Psoriatic arthropathy.

Design outcomes

Primary

MeasureTime frame
PASI Score improvementTimepoint: treatment period 3 month with 1 month followup

Secondary

MeasureTime frame
Improvement in subjective clinical symptoms of Kitibha, assessed using graded scoring: Scaling (Kina) Itching (Kandu) Dryness (Rukshata) Discoloration (Shyava) Comparative efficacy of Ayurvedic intervention versus Methotrexate in: Overall symptom relief Rate and extent of clinical improvement Safety and tolerability profile, assessed by: Hematological parameters (CBC) Liver function tests (LFT) Renal function tests (RFT) Blood sugar (RBS) Lipid profile Thyroid profileTimepoint: treatment period 3 months with follow up once a month

Countries

India

Contacts

Public ContactDr Shalini

Banaras Hindu University

dr.shalini@bhu.ac.in8114413534

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026